Benorilate

Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis[1][2][3][4].

Product Specifications

CAS Number

[5003-48-5]

Product Name Alternative

Salipran

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Benorilate.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(OC1=CC=C(NC(C)=O)C=C1)C2=CC=CC=C2OC(C)=O

Molecular Formula

C17H15NO5

Molecular Weight

313.30

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3 (5826) :545-7.|[2]Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15 (8-9) :743-9.|[3]Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8.|[4]A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105.